RU2370535C2 - Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела - Google Patents

Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела Download PDF

Info

Publication number
RU2370535C2
RU2370535C2 RU2005103627/13A RU2005103627A RU2370535C2 RU 2370535 C2 RU2370535 C2 RU 2370535C2 RU 2005103627/13 A RU2005103627/13 A RU 2005103627/13A RU 2005103627 A RU2005103627 A RU 2005103627A RU 2370535 C2 RU2370535 C2 RU 2370535C2
Authority
RU
Russia
Prior art keywords
cells
transplant
inducing
taic
cell
Prior art date
Application number
RU2005103627/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2005103627A (ru
Inventor
Бернд Карл Фридрих КРЕМЕР (DE)
Бернд Карл Фридрих КРЕМЕР
Фред ФЕНДРИХ (DE)
Фред ФЕНДРИХ
Марен РУНКЕ (DE)
Марен РУНКЕ
Original Assignee
Бластикон Биотехнологише Форшунг Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бластикон Биотехнологише Форшунг Гмбх filed Critical Бластикон Биотехнологише Форшунг Гмбх
Publication of RU2005103627A publication Critical patent/RU2005103627A/ru
Application granted granted Critical
Publication of RU2370535C2 publication Critical patent/RU2370535C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/17Monocytes; Macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22Immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/418Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/24Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2005103627/13A 2002-07-12 2003-07-11 Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела RU2370535C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10231655A DE10231655A1 (de) 2002-07-12 2002-07-12 Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
DE10231655.4 2002-07-12

Publications (2)

Publication Number Publication Date
RU2005103627A RU2005103627A (ru) 2005-08-27
RU2370535C2 true RU2370535C2 (ru) 2009-10-20

Family

ID=30009939

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005103627/13A RU2370535C2 (ru) 2002-07-12 2003-07-11 Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела

Country Status (18)

Country Link
US (1) US20060286670A1 (https=)
EP (2) EP1492869B9 (https=)
JP (1) JP2005532803A (https=)
CN (1) CN100523176C (https=)
AT (2) ATE309331T1 (https=)
AU (1) AU2003250939B2 (https=)
BR (1) BR0312693A (https=)
CA (1) CA2492383A1 (https=)
DE (3) DE10231655A1 (https=)
DK (2) DK1557462T3 (https=)
ES (3) ES2304647T3 (https=)
IL (3) IL166021A0 (https=)
NO (1) NO20050719L (https=)
PT (2) PT1557462E (https=)
RU (1) RU2370535C2 (https=)
SI (3) SI1557462T1 (https=)
WO (1) WO2004007701A1 (https=)
ZA (2) ZA200501054B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10362002B4 (de) 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
KR20060040671A (ko) * 2003-07-11 2006-05-10 블라스티콘 바이오테크놀로지셰 포르슝 게엠베하 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
EP1928479B1 (en) * 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
WO2008090901A1 (ja) * 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP5436905B2 (ja) * 2009-03-26 2014-03-05 テルモ株式会社 シート状細胞培養物の製造方法
JP5667357B2 (ja) * 2009-11-30 2015-02-12 テルモ株式会社 シート状細胞培養物の製造方法
CN101812428A (zh) * 2010-04-26 2010-08-25 西北农林科技大学 一种乳腺上皮细胞的组织块种植方法
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍t細胞応答増強剤
DE102011004335A1 (de) 2011-02-17 2012-08-23 Thomas Grammel Verfahren zur Herstellung eines Vakzins
JP5727665B2 (ja) * 2014-12-11 2015-06-03 テルモ株式会社 シート状細胞培養物の製造方法
JP5893786B2 (ja) * 2015-04-02 2016-03-23 テルモ株式会社 シート状細胞培養物の製造方法
KR102769850B1 (ko) * 2015-07-03 2025-02-20 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 조절 t 세포를 수득하는 방법 및 이의 용도
JP6903866B2 (ja) * 2016-01-27 2021-07-14 国立大学法人 熊本大学 血液由来単球の増殖誘導方法
JP6140322B2 (ja) * 2016-02-24 2017-05-31 テルモ株式会社 シート状細胞培養物の製造方法
JP6490738B2 (ja) * 2017-04-28 2019-03-27 テルモ株式会社 シート状細胞培養物の製造方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Il-6阻害剤を含有する喘息の治療剤
JP6657452B2 (ja) * 2019-02-27 2020-03-04 テルモ株式会社 シート状細胞培養物の製造方法
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
JP7002497B2 (ja) * 2019-06-20 2022-01-20 テルモ株式会社 シート状細胞培養物の製造方法
JP6872051B2 (ja) * 2020-02-05 2021-05-19 テルモ株式会社 シート状細胞培養物の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
JP3926842B2 (ja) * 1995-03-08 2007-06-06 ザ・スクリプス・リサーチ・インステイチユート 抗原提示系およびt−細胞の活性化方法
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
DE60108661T2 (de) * 2000-11-14 2006-01-05 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUCKLE A.M. et al., Colony-stimulating factors and interferon-gamma differentially affect cell surface molecules shared by monocytes and neutrophils, Clin. Exp.Immunol., 1990, v.81, n.2, p.339-345. TANAKA J. et al., The role of accessory cells in allogeneic peripheral blood stem cell transplantation, Int. J. Hematol., 1999, v.69, n.2, p.70-74. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата

Also Published As

Publication number Publication date
IL166021A0 (en) 2006-01-15
EP1492869B1 (en) 2005-11-09
DE10231655A1 (de) 2004-02-26
NO20050719L (no) 2005-04-04
ES2310711T3 (es) 2009-01-16
ZA200601074B (en) 2007-11-28
SI1644484T1 (sl) 2009-02-28
IL172854A0 (en) 2006-06-11
DK1557462T3 (da) 2008-06-23
DE60320009D1 (de) 2008-05-08
RU2005103627A (ru) 2005-08-27
CN1681918A (zh) 2005-10-12
DK1492869T3 (da) 2006-03-06
EP1557462B1 (en) 2008-03-26
ZA200501054B (en) 2005-08-30
EP1492869B9 (en) 2006-05-24
DE60302231D1 (de) 2005-12-15
ES2252696T3 (es) 2006-05-16
PT1644484E (pt) 2008-10-21
SI1492869T1 (sl) 2006-04-30
DE60320009T2 (de) 2009-05-20
CA2492383A1 (en) 2004-01-22
JP2005532803A (ja) 2005-11-04
CN100523176C (zh) 2009-08-05
IL166021A (en) 2010-05-17
SI1557462T1 (sl) 2008-08-31
EP1557462A2 (en) 2005-07-27
PT1557462E (pt) 2008-06-18
ATE390480T1 (de) 2008-04-15
ATE309331T1 (de) 2005-11-15
ES2304647T3 (es) 2008-10-16
DE60302231T2 (de) 2006-07-20
BR0312693A (pt) 2005-04-26
WO2004007701A1 (en) 2004-01-22
AU2003250939A1 (en) 2004-02-02
EP1492869A1 (en) 2005-01-05
EP1557462A3 (en) 2006-02-01
AU2003250939B2 (en) 2008-05-22
HK1071586A1 (en) 2005-07-22
US20060286670A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
RU2370535C2 (ru) Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела
JP6089004B2 (ja) 免疫調節活性を有する細胞集団、単離方法および使用
US20100255009A1 (en) Methods for Inducing Mixed Donor-Recipient Chimerism in an Allograft Transplant Recipient
JP2002502823A (ja) 移植における補刺激遮断および混合キメラ現象
US11701392B2 (en) Compositions for establishing mixed chimerism and methods of manufacture thereof
RU2346041C2 (ru) Аутологичные клетки моноцитарного происхождения, индуцирующие аутотолерантность, и их применение в фармацевтических препаратах
Scherer et al. Immunologic considerations for therapeutic strategies utilizing allogeneic hepatocytes: hepatocyte-expressed membrane-bound major histocompatibility complex class I antigen sensitizes while soluble antigen suppresses the immune response in rats
WO2013076245A1 (en) Allogeneic immune response control
KR20050018998A (ko) 단구성 기원의 이식 조직편 허용 유도성 세포, 및 이의생성 방법 및 용도
HK1071586B (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
JP2009521459A (ja) 肝機能障害治療において肝前駆細胞を用いる方法
HK1088926B (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
ISCHEMIC 0005 REDUCED DOSE-ADAPTED MMF EXPOSURE UNDER PROTON PUMP INHIBITOR CO-MEDICATION IN STABLE HEART TRANSPLANT RECIPIENTS
TW201907949A (zh) 西瑞香素於預防組織或器官移植排斥或是移植物抗宿主疾病之用途
MX2008008333A (en) Method of using hepatic progenitors in treating liver dysfunction

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20100712